Accordingly, in this study we evaluated Trop-2 expression level in 90 high-grade serous ovarian carcinomas and tested for the first time the activity of SG, against nine primary ovarian cancer cell lines, with serous and clear cells histology, with differential Trop-2 expression. This evidence concerns the gene TACSTD2 and ovarian serous carcinoma.